Trade Lyra Therapeutics, Inc. - LYRA CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.11 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Lyra Therapeutics Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 4.34 |
| Open* | 4.18 |
| 1-Year Change* | -26.02% |
| Day's Range* | 3.81 - 4.25 |
| 52 wk Range | 1.86-6.48 |
| Average Volume (10 days) | 48.27K |
| Average Volume (3 months) | 3.39M |
| Market Cap | 186.79M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 49.55M |
| Revenue | 1.24M |
| EPS | -1.59 |
| Dividend (Yield %) | N/A |
| Beta | -0.14 |
| Next Earnings Date | Nov 6, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 21, 2023 | 4.34 | 0.06 | 1.40% | 4.28 | 4.44 | 4.17 |
| Sep 20, 2023 | 4.37 | -0.32 | -6.82% | 4.69 | 4.76 | 4.17 |
| Sep 19, 2023 | 4.79 | 0.23 | 5.04% | 4.56 | 4.81 | 4.55 |
| Sep 18, 2023 | 4.55 | 0.38 | 9.11% | 4.17 | 4.68 | 4.13 |
| Sep 15, 2023 | 4.33 | -0.31 | -6.68% | 4.64 | 4.77 | 4.30 |
| Sep 14, 2023 | 4.72 | 0.13 | 2.83% | 4.59 | 5.01 | 4.59 |
| Sep 13, 2023 | 4.65 | 0.21 | 4.73% | 4.44 | 4.95 | 4.42 |
| Sep 12, 2023 | 4.55 | -0.18 | -3.81% | 4.73 | 4.89 | 4.30 |
| Sep 11, 2023 | 4.22 | 0.38 | 9.90% | 3.84 | 4.26 | 3.78 |
| Sep 8, 2023 | 3.78 | 0.12 | 3.28% | 3.66 | 3.91 | 3.58 |
| Sep 7, 2023 | 3.74 | 0.24 | 6.86% | 3.50 | 3.83 | 3.37 |
| Sep 6, 2023 | 3.55 | 0.07 | 2.01% | 3.48 | 3.60 | 3.37 |
| Sep 5, 2023 | 3.46 | 0.14 | 4.22% | 3.32 | 3.59 | 3.32 |
| Sep 1, 2023 | 3.47 | 0.14 | 4.20% | 3.33 | 3.62 | 3.33 |
| Aug 31, 2023 | 3.45 | -0.03 | -0.86% | 3.48 | 3.66 | 3.31 |
| Aug 30, 2023 | 3.34 | 0.21 | 6.71% | 3.13 | 3.38 | 3.13 |
| Aug 29, 2023 | 3.29 | 0.16 | 5.11% | 3.13 | 3.41 | 3.13 |
| Aug 28, 2023 | 3.29 | 0.16 | 5.11% | 3.13 | 3.30 | 3.13 |
| Aug 25, 2023 | 3.18 | 0.06 | 1.92% | 3.12 | 3.28 | 3.12 |
| Aug 24, 2023 | 3.15 | 0.04 | 1.29% | 3.11 | 3.16 | 3.11 |
Lyra Therapeutics, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Tuesday, September 26, 2023 | ||
| Time (UTC) 20:20 | Country US
| Event Lyra Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Lyra Therapeutics Inc at Cantor Fitzgerald Global Healthcare ConferenceForecast -Previous - |
| Monday, November 6, 2023 | ||
| Time (UTC) 10:59 | Country US
| Event Q3 2023 Lyra Therapeutics Inc Earnings Release Q3 2023 Lyra Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 1.363 | 0.285 | 0 | 0 | 1.244 |
| Revenue | 1.363 | 0.285 | 0 | 1.244 | |
| Total Operating Expense | 57.669 | 43.9 | 22.209 | 16.519 | 8.503 |
| Selling/General/Admin. Expenses, Total | 17.556 | 14.206 | 9.687 | 4.487 | 3.528 |
| Research & Development | 38.797 | 29.694 | 12.522 | 12.032 | 4.975 |
| Operating Income | -56.306 | -43.615 | -22.209 | -16.519 | -7.259 |
| Interest Income (Expense), Net Non-Operating | 1.041 | 0.102 | 0.082 | 0.213 | 0.036 |
| Other, Net | 0 | 1.194 | |||
| Net Income Before Taxes | -55.265 | -43.513 | -22.127 | -16.306 | -6.029 |
| Net Income After Taxes | -55.278 | -43.513 | -22.127 | -16.306 | -6.029 |
| Net Income Before Extra. Items | -55.278 | -43.513 | -22.127 | -16.306 | -6.029 |
| Net Income | -55.278 | -43.513 | -22.127 | -16.306 | -6.029 |
| Income Available to Common Excl. Extra. Items | -55.278 | -43.513 | -22.242 | -16.306 | -6.029 |
| Income Available to Common Incl. Extra. Items | -55.278 | -43.513 | -22.242 | -16.306 | -6.029 |
| Diluted Net Income | -55.278 | -43.513 | -22.242 | -16.306 | -6.029 |
| Diluted Weighted Average Shares | 30.2357 | 12.9861 | 8.59021 | 12.3996 | 12.3996 |
| Diluted EPS Excluding Extraordinary Items | -1.82824 | -3.35074 | -2.58923 | -1.31505 | -0.48623 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
| Diluted Normalized EPS | -1.79995 | -3.35074 | -2.58923 | -1.31505 | -0.48623 |
| Total Adjustments to Net Income | -0.115 | ||||
| Unusual Expense (Income) | 1.316 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0.458 | 0.41 | 0.011 | 0.359 | 0.993 |
| Total Operating Expense | 16.961 | 17.723 | 15.166 | 15.185 | 27.318 |
| Selling/General/Admin. Expenses, Total | 4.57 | 5.127 | 4.399 | 5.137 | 8.02 |
| Research & Development | 10.799 | 12.596 | 9.451 | 10.048 | 19.298 |
| Operating Income | -16.503 | -17.313 | -15.155 | -14.826 | -26.325 |
| Interest Income (Expense), Net Non-Operating | 0.897 | 1.072 | 0.933 | 0.06 | 0.048 |
| Net Income Before Taxes | -15.606 | -16.241 | -14.222 | -14.766 | -26.277 |
| Net Income After Taxes | -15.618 | -16.255 | -14.235 | -14.766 | -26.277 |
| Net Income Before Extra. Items | -15.618 | -16.255 | -14.235 | -14.766 | -26.277 |
| Net Income | -15.618 | -16.255 | -14.235 | -14.766 | -26.277 |
| Total Adjustments to Net Income | |||||
| Income Available to Common Excl. Extra. Items | -15.618 | -16.255 | -14.235 | -14.766 | -26.277 |
| Income Available to Common Incl. Extra. Items | -15.618 | -16.255 | -14.235 | -14.766 | -26.277 |
| Diluted Net Income | -15.618 | -16.255 | -14.235 | -14.766 | -26.277 |
| Diluted Weighted Average Shares | 43.6764 | 36.8327 | 36.8994 | 36.8264 | 32.4204 |
| Diluted EPS Excluding Extraordinary Items | -0.35758 | -0.44132 | -0.38578 | -0.40096 | -0.81051 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.33389 | -0.44132 | -0.3626 | -0.40096 | -0.81051 |
| Revenue | 0.458 | 0.41 | 0.011 | 0.359 | 0.993 |
| Unusual Expense (Income) | 1.592 | 1.316 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 100.829 | 47.918 | 75.917 | 10.119 | 24.927 |
| Cash and Short Term Investments | 97.894 | 45.747 | 74.593 | 9.808 | 23.888 |
| Cash & Equivalents | 32.55 | 45.747 | 74.593 | 9.808 | 23.888 |
| Total Receivables, Net | 0 | 0.167 | |||
| Prepaid Expenses | 2.935 | 2.171 | 1.324 | 0.311 | 0.872 |
| Total Assets | 109.968 | 54.867 | 80.83 | 14.963 | 25.359 |
| Property/Plant/Equipment, Total - Net | 4.466 | 5.858 | 4.466 | 3.419 | 0.103 |
| Property/Plant/Equipment, Total - Gross | 8.64 | 9.737 | 7.344 | 6.248 | 2.905 |
| Accumulated Depreciation, Total | -4.174 | -3.879 | -2.878 | -2.829 | -2.802 |
| Other Long Term Assets, Total | 4.673 | 1.091 | 0.447 | 1.425 | 0.329 |
| Total Current Liabilities | 14.47 | 18.246 | 4.884 | 5.208 | 1.96 |
| Accounts Payable | 2.616 | 3.125 | 0.922 | 1.069 | 0.631 |
| Accrued Expenses | 10.579 | 5.332 | 3.962 | 4.139 | 1.329 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 29.214 | 20.551 | 6.338 | 7.635 | 2.08 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 14.744 | 2.305 | 1.454 | 2.427 | 0.12 |
| Total Equity | 80.754 | 34.316 | 74.492 | 7.328 | 23.279 |
| Redeemable Preferred Stock | 0 | 130.666 | 130.353 | ||
| Common Stock | 0.032 | 0.013 | 0.013 | 0.008 | 0.006 |
| Additional Paid-In Capital | 329.387 | 227.7 | 224.363 | 4.411 | 4.371 |
| Retained Earnings (Accumulated Deficit) | -248.675 | -193.397 | -149.884 | -127.757 | -111.451 |
| Total Liabilities & Shareholders’ Equity | 109.968 | 54.867 | 80.83 | 14.963 | 25.359 |
| Total Common Shares Outstanding | 31.8277 | 13.0072 | 12.9324 | 12.3996 | 12.3996 |
| Other Current Liabilities, Total | 1.275 | 9.789 | |||
| Short Term Investments | 65.344 | ||||
| Other Equity, Total | 0.01 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 84.799 | 100.829 | 112.23 | 122.381 | 40.555 |
| Cash and Short Term Investments | 82.707 | 97.894 | 109.558 | 120.669 | 33.755 |
| Cash & Equivalents | 22.019 | 32.55 | 109.558 | 120.669 | 33.755 |
| Prepaid Expenses | 2.092 | 2.935 | 2.343 | 1.383 | 1.8 |
| Total Assets | 93.868 | 109.968 | 119.463 | 130.035 | 47.345 |
| Property/Plant/Equipment, Total - Net | 3.829 | 4.466 | 4.361 | 4.869 | 5.384 |
| Property/Plant/Equipment, Total - Gross | 8.64 | 9.085 | 9.314 | 9.543 | |
| Accumulated Depreciation, Total | -4.174 | -4.724 | -4.445 | -4.159 | |
| Other Long Term Assets, Total | 5.24 | 4.673 | 2.872 | 2.785 | 1.406 |
| Total Current Liabilities | 14.154 | 14.47 | 13.605 | 10.607 | 21.965 |
| Accounts Payable | 3.951 | 2.616 | 2.9 | 1.67 | 2.408 |
| Accrued Expenses | 8.693 | 10.579 | 7.975 | 6.391 | 5.334 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 27.777 | 29.214 | 26.241 | 23.786 | 24.088 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 13.623 | 14.744 | 12.636 | 13.179 | 2.123 |
| Total Equity | 66.091 | 80.754 | 93.222 | 106.249 | 23.257 |
| Common Stock | 0.032 | 0.032 | 0.032 | 0.032 | 0.013 |
| Additional Paid-In Capital | 331.001 | 329.387 | 327.63 | 325.891 | 228.552 |
| Retained Earnings (Accumulated Deficit) | -264.93 | -248.675 | -234.44 | -219.674 | -205.308 |
| Total Liabilities & Shareholders’ Equity | 93.868 | 109.968 | 119.463 | 130.035 | 47.345 |
| Total Common Shares Outstanding | 31.8368 | 31.8277 | 31.827 | 31.8264 | 13.0099 |
| Other Current Liabilities, Total | 1.51 | 1.275 | 2.73 | 2.546 | 14.223 |
| Total Receivables, Net | 5 | ||||
| Other Current Assets, Total | 0.329 | 0.329 | |||
| Short Term Investments | 60.688 | 65.344 | |||
| Other Equity, Total | -0.012 | 0.01 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -55.278 | -43.513 | -22.127 | -16.306 | -6.029 |
| Cash From Operating Activities | -43.385 | -25.82 | -21.143 | -13.754 | -6.64 |
| Cash From Operating Activities | 1.067 | 1.001 | 0.095 | 0.027 | 0.082 |
| Non-Cash Items | 6.271 | 2.77 | 1.768 | 0.411 | -0.772 |
| Changes in Working Capital | 4.555 | 13.922 | -0.879 | 2.114 | 0.079 |
| Cash From Investing Activities | -65.006 | -3.385 | -1.775 | -0.211 | -0.037 |
| Capital Expenditures | -0.164 | -3.385 | -1.775 | -0.211 | -0.037 |
| Cash From Financing Activities | 96.257 | 0.359 | 87.703 | -0.115 | 29.213 |
| Financing Cash Flow Items | -4.246 | -0.245 | -2.589 | -0.226 | -0.299 |
| Issuance (Retirement) of Stock, Net | 100.503 | 0.604 | 90.292 | 0.111 | 29.012 |
| Issuance (Retirement) of Debt, Net | 0 | 0.5 | |||
| Net Change in Cash | -12.134 | -28.846 | 64.785 | -14.08 | 22.536 |
| Other Investing Cash Flow Items, Total | -64.842 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -16.255 | -55.278 | -41.043 | -21.496 | -7.012 |
| Cash From Operating Activities | -15.85 | -43.385 | -31.221 | -20.375 | -11.905 |
| Cash From Operating Activities | 0.284 | 1.067 | 0.845 | 0.566 | 0.28 |
| Non-Cash Items | 0.884 | 6.271 | 3.69 | 1.951 | 0.844 |
| Changes in Working Capital | -0.763 | 4.555 | 5.287 | -1.396 | -6.017 |
| Cash From Investing Activities | 5.315 | -65.006 | -0.136 | -0.107 | -0.093 |
| Capital Expenditures | -0.045 | -0.164 | -0.136 | -0.107 | -0.093 |
| Cash From Financing Activities | 0.004 | 96.257 | 96.257 | 96.493 | 0.006 |
| Financing Cash Flow Items | 0 | -4.246 | -4.246 | -4.01 | -0.002 |
| Issuance (Retirement) of Stock, Net | 0.004 | 100.503 | 100.503 | 100.503 | 0.008 |
| Net Change in Cash | -10.531 | -12.134 | 64.9 | 76.011 | -11.992 |
| Other Investing Cash Flow Items, Total | 5.36 | -64.842 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Lyra Therapeutics, Inc. Company profile
About Lyra Therapeutics Inc
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on development and commercialization of novel drug and delivery solutions for the treatment of patients with ear, nose, and throat (ENT) diseases. Its technology platform, XTreo, is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210 and LYR-220, are bioresorbable polymeric matrices administered in a non-invasive, in-office procedure to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis (CRS). LYR-210 is an anti-inflammatory implantable drug matrix based on its XTreo platform that is designed to elute mometasone furoate (MF) to the inflamed mucosal tissue for up to six months in surgically naive CRS patients. LYR-220 is an investigative therapy for CRS patients with and without nasal polyps.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Lyra Therapeutics Inc revenues increased from $0K to $285K. Net loss applicable to common stockholders increased 96% to $43.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase from $12.3M to $29.2M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
480 Arsenal Way
WATERTOWN
MASSACHUSETTS 02472
US
Income Statement
- Annual
- Quarterly
News
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023
Cable coils near lows ahead of Fed and BoE rate decisions
It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.
14:16, 19 September 2023
FTSE 100 Technical Outlook - 18 September 2023
In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.
06:55, 19 September 2023
Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally
The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.
13:46, 15 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com